| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | $105.71 | $113.53B | Sell |
J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression
http://www.zacks.com/stock/news/357836/jjs-jnj-nasal-spray-spravato-gets-fda-nod-for-depression?cid=CS-ZC-FT-357836
Mar 06, 2019 - J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression
0
3 Big Pharmas Trying to Pop the Rebate Bubble
https://www.fool.com/investing/2019/03/06/3-big-pharmas-trying-to-pop-the-rebate-bubble.aspx?source=iedfolrf0000001
Mar 06, 2019 - Pharmaceutical companies are suddenly eager to lower drug prices.
0
Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates
http://www.zacks.com/stock/news/357341/aduro-adro-q4-earnings-and-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-357341
Feb 28, 2019 - Wider-than-expected loss affects Aduro (ADRO) in the fourth quarter. Also, revenues lag estimates.
0
United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
http://www.zacks.com/stock/news/357300/united-therapeutics-uthr-q4-earnings-sales-beat-estimates?cid=CS-ZC-FT-357300
Feb 28, 2019 - United Therapeutics (UTHR) beats estimates for both earnings and sales in the fourth quarter. Stock up.
0
Corcept (CORT) Q4 Earnings Beat Estimates, Revenues In Line
http://www.zacks.com/stock/news/357024/corcept-cort-q4-earnings-beat-estimates-revenues-in-line?cid=CS-ZC-FT-357024
Feb 26, 2019 - Corcept (CORT) earnings beat estimates in the fourth quarter of 2018 on increased revenues.
0
Merck to Buy Immunotherapy Developer Immune Design for $300M
http://www.zacks.com/stock/news/356654/merck-to-buy-immunotherapy-developer-immune-design-for-%24300m?cid=CS-ZC-FT-356654
Feb 22, 2019 - Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.
0
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-ZC-FT-356445
Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
0
Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review
http://www.zacks.com/stock/news/356394/dow-30-stock-roundup-wmt-earnings-beat-mrks-keytruda-sbla-gets-priority-review?cid=CS-ZC-FT-356394
Feb 22, 2019 - The index endured a holiday-shortened but volatile week.
0
Allergan Responds to Investor's Call for CEO/Chair Role Split
http://www.zacks.com/stock/news/355578/allergan-responds-to-investors-call-for-ceo-chair-role-split?cid=CS-ZC-FT-355578
Feb 20, 2019 - Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
0
Eli Lilly and Co (LLY) Files 10-K for the Fiscal Year Ended on December 31, 2018
http://www.gurufocus.com/news/818630/eli-lilly-and-co-lly-files-10k-for-the-fiscal-year-ended-on-december-31-2018
Feb 19, 2019 - Eli Lilly and Co (LLY) Files 10-K for the Fiscal Year Ended on December 31, 2018, Stocks: LLY, release date:Feb 19, 2019
0